Clinical trials: Bipolar Disorder With Psychotic Features
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders.
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar, Psychoses
- Trial name
- NCT01196858
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- University Hospital of North Norway
Schizophrenia, Schizoaffective Disorder
Academic-Community EPINET (AC-EPINET)
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features
- Trial name
- AC-EPINET (NCT04497857)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Indiana University
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Severe Bipolar I Disorder (Diagnosis), Bipolar I Disorder, Most Recent Episode Mixed, in Remission
FIbrosis and Steatosis in Patients With Psychiatric Illness
Background: Severe psychiatric diseases (schizophrenia, bipolarity, depression, anxious syndrome) are often associated with a metabolic syndrome, including Non-Alcoholic Steato Hepatitis, probably misdiagnosed in patients with…
- Conditions
- Severe Bipolar I Disorder (Diagnosis), Bipolar I Disorder, Most Recent Episode Mixed, in Remission, Depression Psychotic Feature, Mood-Incongruent Delusion
- Trial name
- FibroPsy (NCT05965232)
- Testing
- Fibroscan
- Where
- France
- Volunteers
- 385 people
- Sponsor
- Centre Hospitalier Esquirol
Schizophrenia, Schizoaffective Disorder
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01570972
- Testing
- Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Arizona
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features
Transition Care for FEP
This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care.
- Conditions
- Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features
- Trial name
- TCT FEP (NCT07713849)
- Testing
- Transition Care Team
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Chicago